The Selective Vasopressin Type 1a Receptor Agonist Selepressin (FE 202158) Blocks Vascular Leak in Ovine Severe Sepsis*

Objective:To determine if the selective vasopressin type 1a receptor agonist selepressin (FE 202158) is as effective as the mixed vasopressin type 1a receptor/vasopressin V2 receptor agonist vasopressor hormone arginine vasopressin when used as a titrated first-line vasopressor therapy in an ovine model of Pseudomonas aeruginosa pneumonia-induced severe sepsis. Design:Prospective, randomized, controlled laboratory experiment. Setting:University animal research facility. Subjects:Forty-five chronically instrumented sheep. Interventions:Sheep were anesthetized, insufflated with cooled cotton smoke via tracheostomy, and P. aeruginosa were instilled into their airways. They were then placed on assisted ventilation, awakened, and resuscitated with lactated Ringer’s solution titrated to maintain hematocrit ± 3% from baseline levels. If, despite fluid management, mean arterial pressure fell by more than 10 mm Hg from baseline level, an additional continuous IV infusion of arginine vasopressin or selepressin was titrated to raise and maintain mean arterial pressure within no less than 10 mm Hg from baseline level. Effects of combination treatment of selepressin with the selective vasopressin V2 receptor agonist desmopressin were similarly investigated. Measurements and Main Results:In septic sheep, MAP fell by ~30 mm Hg, systemic vascular resistance index decreased by ~50%, and ~7 L of fluid were retained over 24 hours; this fluid accumulation was partially reduced by arginine vasopressin and almost completely blocked by selepressin; and combined infusion of selepressin and desmopressin increased fluid accumulation to levels similar to arginine vasopressin treatment. Conclusions:Resuscitation with the selective vasopressin type 1a receptor agonist selepressin blocked vascular leak more effectively than the mixed vasopressin type 1a receptor/vasopressin V2 receptor agonist arginine vasopressin because of its lack of agonist activity at the vasopressin V2 receptor.

[1]  R. Ring The central vasopressinergic system: examining the opportunities for psychiatric drug development. , 2005, Current pharmaceutical design.

[2]  P. Rivière,et al.  Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V1a Receptor Full Agonist for the Treatment of Vasodilatory Hypotension , 2011, Journal of Pharmacology and Experimental Therapeutics.

[3]  David T. Huang,et al.  Implementation of Early Goal-Directed Therapy for Severe Sepsis and Septic Shock: A Decision Analysis , 2008 .

[4]  D. Herndon,et al.  EFFECTS OF SEVERE SMOKE INHALATION INJURY AND SEPTIC SHOCK ON GLOBAL HEMODYNAMICS AND MICROVASCULAR BLOOD FLOW IN SHEEP , 2006, Shock.

[5]  D. Traber Selective V1a receptor agonists in experimental septic shock , 2007, Critical Care.

[6]  J. Russell Vasopressin in vasodilatory and septic shock , 2007, Current opinion in critical care.

[7]  H. Bruining,et al.  Vasopressin deficiency contributes to the vasodilation of septic shock. , 1998, Circulation.

[8]  P. Talke,et al.  Positive End-expiratory Pressure Ventilation Increases Extravascular Lung Water Due to a Decrease in Lung Lymph Flow , 2006, Anaesthesia and intensive care.

[9]  J. Vincent,et al.  Role of selective V1a receptor agonism in ovine septic shock* , 2011, Critical care medicine.

[10]  D. Fisher,et al.  Arginine vasopressin metabolic clearance and production rates in fetal sheep, pregnant ewes, and lambs. , 1984, Developmental Pharmacology and Therapeutics.

[11]  E. Rivers The outcome of patients presenting to the emergency department with severe sepsis or septic shock , 2006, Critical care.

[12]  A. Feydy,et al.  Depletion of neurohypophyseal content of vasopressin in septic shock. , 2002, Critical care medicine.

[13]  K. Takeuchi,et al.  Modification of &agr;1-adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis* , 2002, Critical care medicine.

[14]  Didier Payen,et al.  A positive fluid balance is associated with a worse outcome in patients with acute renal failure , 2008, Critical care.

[15]  N. Morgenthaler,et al.  The vasopressin and copeptin response to infection, severe sepsis, and septic shock* , 2009, Critical care medicine.

[16]  D. Traber,et al.  A novel antibiotic based long-term model of ovine smoke inhalation injury and septic shock. , 2010, Burns : journal of the International Society for Burn Injuries.

[17]  C. Sprung,et al.  Sepsis in European intensive care units: Results of the SOAP study* , 2006, Critical care medicine.

[18]  D. Herndon,et al.  THE INHIBITION OF INDUCIBLE NITRIC OXIDE SYNTHASE IN OVINE SEPSIS MODEL , 2006, Shock.

[19]  B. Mouillac,et al.  Structural bases of vasopressin/oxytocin receptor function. , 1998, The Journal of endocrinology.

[20]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.

[21]  M. Knepper Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. , 1997, The American journal of physiology.

[22]  J. Vincent,et al.  Low-dose vasopressin in the treatment of septic shock in sheep. , 2003, American journal of respiratory and critical care medicine.

[23]  D. Landry,et al.  Endogenous and exogenous vasopressin in shock , 2007, Current opinion in critical care.

[24]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[25]  G. Tsujimoto,et al.  Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. , 2004, Molecular pharmacology.

[26]  D. Traber,et al.  Physiology of the vasopressin receptors. , 2008, Best practice & research. Clinical anaesthesiology.

[27]  J. Jacobson,et al.  Novel therapies for microvascular permeability in sepsis. , 2007, Current drug targets.

[28]  Sangeeta Mehta,et al.  Vasopressin versus norepinephrine infusion in patients with septic shock. , 2008, The New England journal of medicine.

[29]  D. Annane,et al.  Circulating vasopressin levels in septic shock. , 2003, Critical care medicine.

[30]  J. Kaufmann,et al.  Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP) , 2003, Journal of thrombosis and haemostasis : JTH.

[31]  O. Lesur,et al.  Review article: Organ per fusion/permeabilityrelated effects of norepinephrine and vasopressin in sepsis , 2006, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[32]  D. Angus,et al.  Epidemiology of severe sepsis around the world. , 2006, Endocrine, metabolic & immune disorders drug targets.

[33]  Taka-aki Nakada,et al.  Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality* , 2011, Critical care medicine.

[34]  M. Westphal,et al.  Selective V(1a) agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. , 2012, American journal of physiology. Heart and circulatory physiology.

[35]  P. Rivière,et al.  New, potent, selective, and short-acting peptidic V1a receptor agonists. , 2011, Journal of medicinal chemistry.

[36]  K. Takeuchi,et al.  Deactivation of Norepinephrine by Peroxynitrite as a New Pathogenesis in the Hypotension of Septic Shock , 2003, Anesthesiology.

[37]  A. Gordon Vasopressin in Septic Shock , 2011 .

[38]  D. Angus,et al.  Long-term outcomes from sepsis , 2007, Current infectious disease reports.

[39]  M. Singer,et al.  Vasopressin: Mechanisms of action on the vasculature in health and in septic shock , 2007, Critical care medicine.

[40]  J. Howl,et al.  Molecular pharmacology of V1a vasopressin receptors. , 1995, General pharmacology.

[41]  D. Herndon,et al.  A novel animal model of sepsis after acute lung injury in sheep* , 2002, Critical care medicine.

[42]  C. Ducrocq,et al.  Oxidation and nitration of catecholamines by nitrogen oxides derived from nitric oxide. , 1997, Nitric oxide : biology and chemistry.

[43]  D. Herndon,et al.  NOVEL OVINE MODEL OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS-INDUCED PNEUMONIA AND SEPSIS , 2007, Shock.

[44]  S. Jard,et al.  Vasopressin receptors. A historical survey. , 1998, Advances in experimental medicine and biology.

[45]  H. Caldwell 25 Oxytocin and Vasopressin: Genetics and Behavioral Implications , 2006 .

[46]  Aditi Sinha,et al.  The authors reply. , 2015, Kidney international.

[47]  D. Fisher,et al.  DDAVP (1-desamino-8-D-arginine vasopressin) clearance rate. , 1984, Acta endocrinologica.

[48]  H. Iwao,et al.  Nitric Oxide May Participate in V2 Vasopressin‐Receptor-Mediated Renal Vasodilation , 1994, Journal of cardiovascular pharmacology.